Factotum hematologist but esp AL Amyloidosis, gene tx for HbSS, & HTLV associated ATLL. Professor and Heme/onc Program Director @The_BMC. The J is for jenius.
Boston MA
Joined July 2013
- Tweets1.7K
- Following2.9K
- Followers2.9K
- Likes12.1K
Cilta-cel and I had a toxic relationship. Glad to finally have an alternative.
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r
Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Phase 1 Study of Anito-cel, a D-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma." The graph shows progression-free survival among all patients who received anito-cel. The NEJM identity sits at the bottom.
Program Director Tip:
The easiest and biggest green flag in a fellowship interview is when a candidate expresses gratituted towards the mentors.
In my experience it is a reliable marker for someone that would be good to work with.
"Jehovah’s Witnesses love life and want the best available medical care." Amen.
Also clarifying that this is an individual decision and one should not expect all JWs to be on board.
Big news - Jehovah’s Witnesses can receive PRBC, platelets FFP etc if they want jw.org/en/global-communicati…
Its remarkable that neither Wyoming or Alaska have an ACGME-accredited internal medicine residency. They must entirely rely on internists to move to the state after training; a major disadvantage. abim.org/media/ep2awh1x/resi…
@SenJohnBarrasso
@lisamurkowski
You know how we used to do ultrasounds to see the baby’s sex… but now it’s an envelope + gender reveal party?
I feel like that’s lymphoma now. We used to do PET scans to assess responses— now the results come as Signatera attachments. @NateraGenetics #Lymphoma
Calling all MA residents: Please support House Bill 4553 to require insurance coverage for medically necessary denta lcare for head & neck cancer pts—before, during & after treatment. A huge treatment barrier!
Contact your state rep: malegislature.gov/Search/Fin…
#HeadNeckCancer
I remember Dr Goss telling us that starting a good clinical trial was like a farmer planting his crops. If you plant it correctly you can relax and enjoy the harvest for years.
ascopost.com/news/january-20…
J Mark Sloan retweeted
Have been working w/ @Jmarksloan on this for a decade: BV-CHEP for 1L ATLL.
@BrJHaem
N=16
CR: 62.5%
ORR: 87.5%
mOS: 15.7m
AlloSCT: 5 pts; mOS: NR
Tox: cytopenias, mucositis, PN
New consideration for aggressive ATLL.
onlinelibrary.wiley.com/doi/…
J Mark Sloan retweeted
What's going to be different with the new IMWG response criteria?
Main changes:
- FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone)
- No more sCR
- Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing.
- 24-hour urine at baseline, and if M-protein present, retest only to confirm CR
- Patients can be considered to have PD if they meet criteria by a variable not considered measurable at baseline (major weakness with current response criteria is that it misses light chain escape).
Next, imaging....
1/7: As Hematology-Oncology Fellowship Program Director, I've reviewed 647 applications this cycle. Every personal statement cites a passion caring for cancer patients, research and teaching. 85% explicitly prefer academic medicine. No one
mentions wanting a career in pharma
6/7: I'm not judging, people should pursue whatever they wish. Industry
work is interesting, important and rewarding. It's when choice becomes survival. When the job you love costs more joy, health, or balance than you can sustain. Make longevity doable, not heroic.
7/7 (199 chars): What do you think? Predicting career longevity
is tricky. Should pharma have its own fellowship track with quotas? PDs, fellows, oncologists—share your take! #MedEd #OncTwitter #AcademicMedicine
This change in V6 CTCAE neutropenia grading is an enormous win for Duffy null patients.
Everyone holding their breath to see which @VPrasadMDMPH shows up @FDACBER :
Evidence based academic oncologist unafraid to speak truth to power
OR
@SecKennedy sycophant endorsing clarithromycin for measles because a few Mennonite kids got better.
This Post is from an account that no longer exists. Learn more